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Conclusions: Several low and high risk factors were 
identified which may assist with tailoring future clinical trial 
QA. RTR are essential due to a baseline level of resubmission, 
which is independent of clinician or site factors. There is a 
scope for modifying RTR QA to include only contouring RTR 
submissions at high volume sites. The lower rate of 
resubmission for cases using IMRT may be a surrogate for 
advanced technology implementation at a particular site. 
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Purpose/Objective: Our Center acquired a mobile electron 
linear accelerator for intraoperative radiation therapy (IORT) 
and the clinical activity started at the end of June 2012. The 
risk assessment performed before the start of clinical activity 
was integrated with a predictive matrix risk analysis (FMECA). 
Two years later an analysis of all the relevant criticalities 
was performed in order to improve quality. The aim of this 
study is to present the results of the method elaborated by 
our Working Group and the application of FMECA prospective 
approach to IORT procedure. 
Materials and Methods: A multidisciplinary Working Group 
was created, including different professional profiles. Each 
member of the Working Group was asked to identify a priori 
the criticalities he/she could meet in the process steps 
concerning his/her specific activity. In this way a list of all 
potential failure modes (FM) occuring in each process step 
was drafted. 
The risk analysis was completed by asking the members of 
the team to evaluate the Risk priority number (RPN) of each 
FM.  
Two years after the beginning of IORT clinical activity, the 
risk analysis was repeated by the Working Group, in order to 
assess the improvement achieved. 
Results: The IORT process was subdivided in 43 steps and 39 
criticalities were identified by the Working Group. They 
represented the issues prospectively investigated according 
to the FMECA method. An Excel worksheet was created, 
inserting in rows: process step, professional figures involved, 
failure mode, potential effects of failure, potential causes of 
failure, preliminary RPN and corrective actions. In the re-
analysis of the process - two years later - the final RPN was 
elaborated and the risk reduction (RR) (preliminary RPN – 
final RPN) was also calculated, in order to assess the weight 
of the corrective measures. The highest score was attributed 
to the misalignement of the internal shield, used to protect 
the underlying normal tissues, with a risk reduction equal to 
20 (25%) after corrective actions. The next critical scores 
were related to the inaccurate placement of the applicator in 
the tumour bed (RR: 28; 43,8%) and the wrong definition of 
the CTV (RR: 48; 75%). Another relevant failure mode was the 
inadequate placement of the dosimeter (gafchromic film) on 
top of the internal shield. In most cases this risk was 
prevented following the 'in vivo dosimetry' Procedure, 
elaborated by our Medical Physicist (RR: 28; 46.7%).  
Conclusions: The FMECA technique has provided a 
prospective systematic method for discovering potential 
failures in IORT procedure; evaluating not only the frequency 
of FM but also their severity and detectability, it has given a 
more complete assessment of the risks. It contributes 
therefore to optimize patient safety right from the start of 
our clinical activity and to improve risk management culture 
among all the professionals involved in the Working Group. 
    
EP-1327   
The definition of an auditable and complete dataset for 
lung cancer patients - the RTTís role 
D. Blair1, M. Brada1, E. Clarke1, C.R. Baker1, A.J. Reilly1, A.F. 
Baker1 
1Clatterbridge Cancer Centre, Radiotherapy, Wirral, United 
Kingdom  
 
Purpose/Objective: The North West area has one of the 
largest number of lung cancer patients in the U.K. Data 
collected for these patients relating to treatment outcome 
and graded toxicities does not currently allow us to 
accurately assess these data. In conjunction with a radiation 
oncology professor and a research fellow, an RTT has been 
heavily involved in the definition, production and design of a 
defined, auditable dataset for lung cancer patients. 
Materials and Methods: Our institution is attempting to 
implement a data warehouse product into its information 
technology structure in order to make information more 
accessible to staff conducting audit and research. In the 
baseline assessments made during the set up of the data 
warehouse, the chair of radiation oncology appraised the 
data collected for patients and a decision was made to 
improve the quantity, and more importantly, the quality of 
the data recorded. On a disease site specific basis, and 
beginning with lung (a large patient group with poor 
outcomes), a work stream was set up in order to define an 
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auditable dataset for lung cancer patients. An RTT and the 
chair of radiation oncology consulted on four occasions over 3 
months, and then consulted on a further 4 occasions over 6 
weeks in conjunction with a clinical research fellow. 
Results: The consultations begun with a loose outline based 
on the journey of the patient from initial diagnosis, through 
methods of biopsy and histological classification, 
encompassing chemotherapy, surgery, and radiotherapy 
treatment. Full medical history and relevant functional 
analysis results give a full background and are included in 
pre-defined scores for associated co-morbidities, and 
dyspnoea, both of which are excellent prognostic indicators. 
Details of diagnostic, planning, on treatment and follow up 
imaging are linked into the current version. All radiotherapy 
plan data, and treatment parameters are included with links 
to volumetric imaging providing an excellent research 
resource. An auditable defined dataset for lung cancer 
patients is now available, and will begin collecting data for 
lung patients in April 2015, pending approval from the Site 
Reference Group and the employment of a team to collect, 
input and quality control the dataset. This dataset will be 
manually collected, and consultations have already begun to 
develop an electronic version which will automatically 
populate information where applicable. 
Conclusions: The RTT has a valuable role to play in the 
definition of functional datasets collected for research 
purposes. The value of the collection and maintenance of 
such databases, and their interaction with other electronic 
systems will become more and more important as the data 
we create, and the evidence we can see drives forward 
changes in practice. 
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Purpose/Objective: Within our Quality Management Program 
(QMP) we implemented a daily peer review round (PRR) to 
validate RT plans prior to treatment commencement (or 
within the first fractions). The purpose of this study is to 
report the outcomes of these rounds and to show how these 
outcomes are used for quality monitoring and improvement. 
Materials and Methods: Following our QMP all patients but 
urgent indications should be presented to the PRR. All 
radiation oncologists (RO) (8), RO residents, 1 Medical 
Physicist (MP) and 1 MP resident participate in the rounds. 
The data presented were collected over a year. A total of 
1391 patients started EBRT treatment. Patient history data 
and images were presented and the treatment indication, 
dose prescription, volume delineation and the dose 
distribution were reviewed. Details of proposed changes were 
collected prospectively within a data-base together with 
tumour site, date of CT-planning and starting treatment 
date. From this data-base several Quality Indicators (QI) were 
defined and are shown in table I. The data were collected 
daily and the results were analysed yearly. The data-base 
allows stratifying all QI by tumour site and technique (3DCRT, 
IMRT or SBRT) as it was done for this study.  
Results: Of the 1391 eligible patients, 801 (58%) were 
presented for peer review. Fig. shows an increase of 
reviewed patients after March because a time slot on Friday 
was blocked to review the cases that had not been presented 
during the week. At least 4/8 radiation oncologists 
participated in 67% of the patient reviews. Table 1 shows the 
results of QI analysed over a year. The number of cases 
requiring changes is similar to those reported by other groups 
performing QA rounds. The higher number of changes is 
linked to volume contouring (4.5%) while the number of cases 
requiring re-planning due to a suboptimal dose distribution is 
significantly lower (1.5%). This is related to the fact that 
while volume delineation is not reviewed by an independent 
RO before starting dose planning, treatment plan and dose 
distribution is performed by a radiation technologist, 
reviewed by a MP and discussed with the RO before being 
presented in the peer review round. The changes were 
stratified by location and technique; however no prevalence 
of one site or a technique could be detected. The time 
between planning CT and start of treatment is within the 
standards set by our department, except for palliative cases.  
 
 
Conclusions: A daily peer review session is feasible and now 
a part of the normal practice in our Department. However, 
not all the patients are reviewed. There’s a need to re-
structure the peer review rounds so that a higher proportion 
of patients are reviewed. As most changes were on 
contouring we are considering creating a peer review round 
